C‐reactive protein and procalcitonin levels in prostate cancer

English (OpenAlex)

AIM: Prostate cancer (PCa) is one of the most common cancers among men in the world. Prostate-specific antigen is the most used biomarker for PCa diagnosis. In this study, we aimed to measure the procalcitonin (PCT) and C-reactive protein (CRP) levels in patients with PCa. METHODS: The patients who underwent transrectal prostate biopsy and transurethral prostate surgery in the last 4 years were included in the study. The patients were divided into two groups according to the pathology reports, group1; benign prostate hyperplasia and group2; prostate cancer. MedCalc Statistical Software version 17.6 was used for statistical analyses. RESULTS: The current study includes 149 patients. There were 118 patients in group 1 and 31 patients in group 2. The mean age of the patients was 66.85 and 69.41 years in groups respectively. Serum CRP and PCT levels were 3.33 and 0.01 in group 4.07 and 0.04 in group 2. Serum PCT levels were significantly higher in patients with PCa. CONCLUSION: We found that the elevated procalcitonin level was associated with prostate cancer. Further studies are needed to define the relationship between procalcitonin and prostate cancer.